Should complete remission, however strictly defined, be the goal for everyone? YES! New York, October 23, 2014 Ola Landgren, M.D., Ph.D. Chief, Myeloma.

Slides:

Advertisements

Similar presentations

13th Annual Hematology & Breast Cancer Update Update in Lymphoma

Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Ravi Vij MD Associate Professor Section of BMT and Leukemia

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Staff Oncologist, Mayo Clinic Arizona

Support for pesticides playing a role in onset of multiple myeloma

Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.

Induction Therapies in Transplant Eligible Patients Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College.

MRD in myeloma UKMF Spring Day Assessment of disease response, CR and beyond. Roger Owen St James’s Institute of Oncology Leeds, UK.

Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 1,2 The Cardiovascular Impact of Carfilzomib in Multiple Myeloma 3 1 Stewart.

OncoTracker James Berenson, MD President and CEO November 2014.

Kovacs G et al. Proc ASH 2014;Abstract 23.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Korde N et al. Proc ASH 2014;Abstract 2105.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Phase I Trial of Autologous CD19-Targeted CAR-Modified T Cells as Consolidation After Purine Analog-Based First-Line Therapy in Patients with Previously.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Corre J et al. Proc ASH 2014;Abstract 180.

Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Cancer Among Native Americans in Arizona and New Mexico Data Provided by Arizona Cancer Registry at the Arizona Department of Health Services and the New.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.

Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.

A Phase Ib Dose Escalation Trial of SAR (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.

1 Genomics and the Human Condition Francis S. Collins, M.D., Ph.D. Dedication of Ken Olsen Science Center Gordon College September 27, 2008.

Palumbo A et al. Proc ASH 2014;Abstract 175.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Increased Incidence of Therapy- Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) vs Fludarabine (F):

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.

Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Value of MRD to Predict PFS in MM: Results From IFM/DFCI 2009

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple.

New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida First-in-Human Trial: BCMA- Targeted CAR.

AIMING FOR EXCELLENCE IN OUTCOMES IN HAEMATOLOGIC MALIGNANCIES Taking a Deeper Approach to Multiple Myeloma Treatment UK/NP/1508/0047c(1) April 2016 A.

Geisler C et al. Proc ASH 2011;Abstract 290.

MRD testing: which platforms, which patients?

Minimal Residual Disease (MRD) in Multiple Myeloma

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Chen R et al. Proc ASH 2015;Abstract 518.

Korde N et al. Proc ASH 2012;Abstract 732.

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

The Role of Minimal Residual Disease in Multiple Myeloma

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

MRD in Myeloma: the Future is Here

Background and update from Myeloma XI Dr John Jones

Karmanos Cancer Institute

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

What is the best frontline regimen for CLL patients

Grövdal M et al. Blood 2008;112:Abstract 223.

Anas Younes, M.D. Memorial Sloan Kettering Cancer Center

Sensitivity and specificity plots of human epididymis protein 4 (HE4) (A and B, respectively) and carbohydrate antigen 125 (CA-125) (C and D, respectively)

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Minimal Residual Disease in Multiple Myeloma

Presentation transcript:

Should complete remission, however strictly defined, be the goal for everyone? YES! New York, October 23, 2014 Ola Landgren, M.D., Ph.D. Chief, Myeloma Service Memorial Sloan-Kettering Cancer Center, New York

Alternative: be lazy, take it easy

“YES ARGUMENTS”

123456

Respect your elders!

Kapoor et al. J Clin Oncol 2013 Importance of good clinical response

“YES ARGUMENTS”

Newer myeloma drugs provide better clinical response Kumar Cancer Treatment Reviews 2010; Korde et al. ASH 2013 CRd

“YES ARGUMENTS”

Kapoor et al. J Clin Oncol 2013 Clinical response to therapy impacts progression-free survival

Clinical response to therapy impacts overall survival Kapoor et al. J Clin Oncol 2013

“YES ARGUMENTS”

Quality matters

At diagnosis Partial response (50% reduction in M protein) Near complete remission (immunofixation pos only) Complete remission (immunofixation neg) 1 × Number of myeloma cells 1 × 10 8 Why stop at CR, when we are not yet done? Cure MRD- Non-quantitative ASO-PCR of bone marrow Quantitative ASO-PCR of bone marrow High quality flow cytometry of bone marrow Deep sequencing of bone marrow 1 × × 10 6 MRD+ 0

Kapoor et al. J Clin Oncol 2013 Clinical response to therapy impacts progression-free survival

Clinical response to therapy impacts overall survival Kapoor et al. J Clin Oncol 2013

Among CR patients, flow cytometry MRD- impacts survival Rawstron et al. J Clin Oncol 2013

Myeloma genetics and MRD status: impact on overall survival Hyperdiploidy, t(11;14), or t(6;14) Gain(1q), del(1p32), t(4;14), t(14;20), t(14;16), or del(17p)

“YES ARGUMENTS”

Myeloma is NOT a Polaroid!

Sustained stringent clinical response to therapy impacts overall survival Kapoor et al. J Clin Oncol 2013

“YES ARGUMENTS”

There is already a literature: we are already doing it! Number of published myeloma MRD studies associated with clinical outcomes Landgren et al. unpublished data

Summary and Conclusions Deeper responses in more patients Deeper responses = better survival Deeper is better, MRD next step forward

Thank you for your attention! Ola Landgren, M.D, Ph.D. Chief, Myeloma Service Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065, USA Phone: